Stocks · News reference

Nexentis’ MitoCareX Announces Expansion Of Drug Discovery Platform Into Disease Pathway Analysis, Adds Bioinformatician To Team

Oct 12, 2026, 12:09 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 7, 2026, 11:34 AMBenzinga Newsdesk
Nexentis Technologies Unit MitoCareX Bio Launches Its Computational Drug Discovery Infrastructure On Google Cloud Platform
The transition is designed to provide MitoCareX with a secure and flexible computing environment for its computational activities and evolving drug discovery requirements. The infrastructure deployment is expected to
NXTS
SEC EDGAROct 6, 2026, 1:30 PMSEC EDGAR
8-K filing — Nexentis Technologies Inc. (NXTS)
Filed: 2026-10-06 AccNo: 0001493152-26-045885 Size: 823 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
NXTS
Globenewswire IncSep 24, 2026, 11:50 AMNexentis Technologies Inc.
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
Nexentis Technologies' subsidiary MitoCareX Bio Ltd. announced the appointment of Prof. Dan T. Major to its Scientific Advisory Board to strengthen its computational drug discovery capabilities. Prof. Major, a computational chemistry expert from Bar-Ilan University, will advise on in silico drug-discovery approaches and computational methods to support MitoCareX's expansion of internal scientific capabilities and prioritization of discovery programs.
NXTS